Estradiol vaginal inserts (4 mu g and 10 mu g) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data Review

sustainable development goals

authors

publication date

  • December 2, 2018

webpage

published in

keywords

  • Dyspareunia
  • VVA
  • estradiol
  • menopause
  • vaginal atrophy

start page

  • 2131

end page

  • 2136

volume

  • 34

issue

  • 12